Cargando…
Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma
OBJECTIVE: LncARSR (lncRNA Activated in RCC with Sunitinib Resistance, ENST00000424980) is a newly identified lncRNA to promote the sunitinib resistance of renal cell carcinoma (RCC), which may contribute to tumorigenesis and progression. This study aimed to explore the association of lncARSR tagSNP...
Autores principales: | Xing, Qianwei, Li, Ran, Xu, Aiming, Qin, Zhiqiang, Tang, Jinyuan, Zhang, Lei, Tang, Min, Han, Peng, Wang, Wei, Qin, Chao, Du, Mulong, Zhang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558481/ https://www.ncbi.nlm.nih.gov/pubmed/31038847 http://dx.doi.org/10.1002/cam4.2160 |
Ejemplares similares
-
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022) -
Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer
por: Zhang, Ke, et al.
Publicado: (2019) -
Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016) -
The value of renal score in both determining surgical strategies and predicting complications for renal cell carcinoma: A systematic review and meta‐analysis
por: Shi, Naipeng, et al.
Publicado: (2020) -
Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)